MedPath

Assessment of CCM in HF With Higher Ejection Fraction

Not Applicable
Recruiting
Conditions
Heart Failure
Heart Failure With Preserved Ejection Fraction
Heart Failure With Mid Range Ejection Fraction
Heart Failure With Moderately Reduced Ejection Fraction
Diastolic Heart Failure
Interventions
Device: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System
Device: OPTIMIZER™ Smart Mini System
Registration Number
NCT05064709
Lead Sponsor
Impulse Dynamics
Brief Summary

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

Detailed Description

The AIM HIGHer Clinical Trial is a prospective, multi-center, randomized, quadruple-blind, sham-controlled, two-part embedded trial of the safety and efficacy of CCM therapy delivered via the OPTIMIZER Smart Mini System in subjects with heart failure and an LVEF ≥40% and ≤70%. Subjects will be enrolled at approximately 150 sites in the US and 75 sites OUS.

All subjects will undergo screening and baseline testing; all eligible subjects will be implanted with the Optimizer System. Subjects will be randomized in a 2:1 ratio to either CCM ON (CCM group) or to CCM OFF (Sham group). The trial will be blinded to the treatment assignment of the device for 18-months. Subjects in the Sham group will have CCM turned ON after completion of the 18-month study visit. Subjects enrolled during Part I (450 subjects) of the trial will continue follow-up through the end of Part II (up to an additional 1,050) and contribute data to both parts of the trial. Each part of the trial is distinguished by a separate scientific purpose. The specific purpose of each part is:

Part I - Establish safety and effectiveness based on functional capacity and health status.

Part II - Establish safety and effectiveness based on clinical outcome data.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1500
Inclusion Criteria
  1. Signed and dated informed consent form;

  2. Male or non-pregnant female, 18 years or older;

  3. Diagnosed with symptomatic heart failure;

  4. LVEF ≥40 and ≤70% (as assessed by site echo);

  5. A. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)

  6. Subjects must meet one of the following conditions:

    • Have stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance.
    • Eligibility for enrollment is maintained for patients on an SGLT2 inhibitor without prescribed concurrent standing loop diuretic therapy if investigators provide instructions for a flexible PRN diuretic regimen (deemed appropriate by the clinician in response to symptoms or weight gain) Note: Stable is defined as no more than a 100% increase or 50% decrease in dose within the last 30 days. A one-time hold of diuretic dosing for 24 hours during the 30-day period is allowed and not an exclusionary event.
Exclusion Criteria
  1. Resting ventricular rate <50 or >110 bpm;
  2. Resting systolic blood pressure <100 or ≥160 mmHg;
  3. BMI greater than 46
  4. Any severe valvular stenotic disease or any severe valvular regurgitation;
  5. Mechanical tricuspid valve;
  6. Complex congenital heart disease;
  7. Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and/or exercise intolerance;
  8. Unable to walk at least 100 meters or walks more than 450 meters during a 6MWT;
  9. A KCCQ CCS score higher than 85;
  10. Hypertrophic, infiltrative/restrictive or inflammatory cardiomyopathy;
  11. Unstable angina pectoris within 30 days prior to study consent;
  12. Acute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;
  13. Receiving cardiac resynchronization therapy (CRT); NOTE: Subjects with active/ongoing cardiac resynchronization therapy (CRT) implanted more than one year ago are eligible for inclusion if they are currently classified as NYHA class III or higher.
  14. Scheduled for a cardiac surgery or a percutaneous cardiac intervention (PCI) or have undergone cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
  15. Myocardial infarction within 90 days prior to study consent;
  16. Prior heart transplant or ventricular assist device;
  17. Planning to become pregnant during the study;
  18. Dialysis (permanent) or GFR <15 ml/min/1.73m2;
  19. Participating in another investigational drug or device study that may interfere with the interpretation of study data;
  20. Currently undergoing active chemotherapeutic and/or radiation treatment for cancer or has a history of chemotherapy during the 2-year period prior to study consent;
  21. Expected lifespan of less than 18 months from time of study consent;
  22. Unable to follow through study protocol for any reasons in the investigator's judgement.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CCM Group (CCM ON)Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini SystemCCM therapy will be turned on in 2/3 of the subjects for the entire duration of the study.
Sham Group (CCM OFF)OPTIMIZER™ Smart Mini SystemCCM therapy will be turned off in 1/3 of the subjects for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.
Primary Outcome Measures
NameTimeMethod
Part 1 Efficacy Endpoint - Change in 6-minute walk distance (6MWD) from baseline to 6 months.6 months

Demonstrate that CCM therapy improves functional capacity in subjects with symptomatic heart failure with LVEF ≥40% and ≤70%. Compare the changes in functional capacity, as measured by the 6-minute walk distance (6MWD), from baseline to 6-months following the randomization date between the two study groups.

Part 1 Efficacy Endpoint - Change in the health status from baseline to 6 months as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS).6 months

Demonstrate that CCM therapy improves health status in subjects with symptomatic heart failure with LVEF ≥40% and ≤60%. Compare the changes in health status, as measured by the KCCQ CSS, from baseline to 6-months following the randomization date between the two study groups.

Part 1 Safety Endpoint - The incidence of Optimizer device- or procedure-related complications within the first 12 months after implant12 months

Compare the composite incidence of Optimizer device-related and procedure-related SAEs (complications) for available data collected from implant to 12 months after the Optimizer implantation procedure to a performance goal of 75% free of complications.

Part 2 Endpoint - The hierarchical composite of mortality, morbidity, and health status outcomes (KCCQ CSS).18 months

Demonstrate that CCM therapy improves a composite endpoint of cardiovascular mortality at 18-months, heart failure hospitalizations at 18-months, urgent heart failure visits requiring IV diuretics at 18-months and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS) at 12-months. Comparison of a hierarchical composite endpoint between the two study groups will be based on the Finkelstein-Schoenfeld global rank method.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (103)

Grandview Medical Group Research, LLC

🇺🇸

Birmingham, Alabama, United States

The University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

CardioVascular Associates of Mesa

🇺🇸

Mesa, Arizona, United States

Chan Heart Rhythm Institute

🇺🇸

Mesa, Arizona, United States

Southwest Cardiovascular Associates

🇺🇸

Mesa, Arizona, United States

Banner Health- Phoenix

🇺🇸

Phoenix, Arizona, United States

Arizona Heart Rhythm

🇺🇸

Phoenix, Arizona, United States

Cardiovascular Consultants, Ltd

🇺🇸

Phoenix, Arizona, United States

HonorHealth

🇺🇸

Scottsdale, Arizona, United States

Pima Heart and Vascular

🇺🇸

Tuscon, Arizona, United States

John Muir Health

🇺🇸

Concord, California, United States

Northbay Heart and Vascular

🇺🇸

Fairfield, California, United States

University of California San Diego

🇺🇸

La Jolla, California, United States

USC Keck School of Medicine

🇺🇸

Los Angeles, California, United States

Cedars Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Valley Clinical Trials Pasadena

🇺🇸

Northridge, California, United States

Valley Clinical Trials- Northridge

🇺🇸

Northridge, California, United States

Sequoia Hospital

🇺🇸

Redwood City, California, United States

University of California Davis Health

🇺🇸

Sacramento, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Hartford Healthcare

🇺🇸

Hartford, Connecticut, United States

Nuvance Health

🇺🇸

Wilton, Connecticut, United States

HCA Florida JFK Hospital

🇺🇸

Atlantis, Florida, United States

Nouvelle Clinical Research LLC

🇺🇸

Cutler Bay, Florida, United States

Holy Cross Hospital

🇺🇸

Fort Lauderdale, Florida, United States

Broward Health

🇺🇸

Fort Lauderdale, Florida, United States

Memorial Healthcare System

🇺🇸

Hollywood, Florida, United States

Baptist Health South Florida

🇺🇸

Miami, Florida, United States

NCA Research Institute - Florida

🇺🇸

Naples, Florida, United States

AdventHealth Orlando

🇺🇸

Orlando, Florida, United States

Revival Clinical Research

🇺🇸

Orlando, Florida, United States

Tallahassee Research Institute

🇺🇸

Tallahassee, Florida, United States

Cleveland Clinic Foundation - Florida Weston Hospital

🇺🇸

Weston, Florida, United States

Piedmont Healthcare

🇺🇸

Atlanta, Georgia, United States

WellStar Health System, Inc

🇺🇸

Marietta, Georgia, United States

Franciscan Health Indianapolis

🇺🇸

Indianapolis, Indiana, United States

Ascension Medical Group St. Vincent

🇺🇸

Indianapolis, Indiana, United States

University of Iowa

🇺🇸

Iowa City, Iowa, United States

MercyOne Iowa Heart

🇺🇸

West Des Moines, Iowa, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

Kansas City Cardiac Arrhythmia Research LLC

🇺🇸

Overland Park, Kansas, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

University of Kentucky Research Foundation

🇺🇸

Lexington, Kentucky, United States

Ochsner Clinic Foundation

🇺🇸

New Orleans, Louisiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Ascension St. John

🇺🇸

Detroit, Michigan, United States

Ascension Providence Hospital

🇺🇸

Southfield, Michigan, United States

Trinity health- Michigan Heart

🇺🇸

Ypsilanti, Michigan, United States

Minneapolis Heart Institute at Abbott Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

North Mississippi Medical Center

🇺🇸

Tupelo, Mississippi, United States

Our Lady of Lourdes

🇺🇸

Camden, New Jersey, United States

Sanger Heart and Vascular

🇺🇸

Charlotte, North Carolina, United States

TriHealth Bethesda

🇺🇸

Cincinnati, Ohio, United States

St. Louis Heart and Vascular

🇺🇸

Bridgeton, Missouri, United States

St. Lukes Hospital Kansas City (Mid America Heart Institute)

🇺🇸

Kansas City, Missouri, United States

Bryan Heart

🇺🇸

Lincoln, Nebraska, United States

Catholic Medical Center

🇺🇸

Manchester, New Hampshire, United States

Jersey Shore University Medical Center

🇺🇸

Edison, New Jersey, United States

St. Luke&#39;s Hospital

🇺🇸

Chesterfield, Missouri, United States

Weill Cornell Medicine

🇺🇸

New York, New York, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Hackensack University Medical Center

🇺🇸

Edison, New Jersey, United States

Cooper Hospital- Cardiovascular Associates of Delaware Valley

🇺🇸

Haddon Heights, New Jersey, United States

Atlantic Health System- Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Rutgers New Jersey Medical School

🇺🇸

Piscataway, New Jersey, United States

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

OhioHealth Research Institute

🇺🇸

Columbus, Ohio, United States

Mercy Health- St. Vincent Medical Center LLC

🇺🇸

Toledo, Ohio, United States

Oklahoma Heart Institute

🇺🇸

Tulsa, Oklahoma, United States

St. Francis Hospital - Tulsa

🇺🇸

Tulsa, Oklahoma, United States

Providence Heart & Vascular

🇺🇸

Portland, Oregon, United States

Bryn Mawr Medical Specialists Association

🇺🇸

Bryn Mawr, Pennsylvania, United States

UPMC Pinnacle Harrisburg

🇺🇸

Harrisburg, Pennsylvania, United States

Penn State Hershey Medical City

🇺🇸

Hershey, Pennsylvania, United States

Lancaster General Hospital

🇺🇸

Lancaster, Pennsylvania, United States

Penn Presbyterian Medical Center

🇺🇸

Philadelphia, Pennsylvania, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Tower Health Reading Hospital

🇺🇸

Reading, Pennsylvania, United States

WellSpan Health

🇺🇸

York, Pennsylvania, United States

Prisma Health Upstate

🇺🇸

Greenville, South Carolina, United States

The Stern Cardiovascular Foundation

🇺🇸

Germantown, Tennessee, United States

Texas Cardiac Arrhythmia Research Foundation

🇺🇸

Austin, Texas, United States

Ascension Seton

🇺🇸

Austin, Texas, United States

Austin Heart

🇺🇸

Austin, Texas, United States

Baylor Scott and White Research Institute

🇺🇸

Dallas, Texas, United States

HCA Medical City Dallas

🇺🇸

Dallas, Texas, United States

Baylor Scott White- All Saints- Fort Worth

🇺🇸

Fort Worth, Texas, United States

Medical City Fort Worth Hospital

🇺🇸

Fort Worth, Texas, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Houston Methodist

🇺🇸

Houston, Texas, United States

Memorial Hermann Texas Medical Center

🇺🇸

Houston, Texas, United States

Heart Rhythm Specialists

🇺🇸

McKinney, Texas, United States

Baylor Scott and White- The Heart Hospital- Plano

🇺🇸

Plano, Texas, United States

Baylor Scott and White Research Institute - Round Rock

🇺🇸

Round Rock, Texas, United States

Methodist Hospital

🇺🇸

San Antonio, Texas, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Peace Health

🇺🇸

Vancouver, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath